Panteleimon D. Mavroudis
机构: Distinguished Scientist - US Head of Quantitative Pharmacology Research, Sanofi
主页: linkedin.com
每年引用次数
引用次数
引用: 643
H-指数: 14
I10-指数 : 15
出版物: 38
Systems biology of circadian-immune interactions.
P.D. Mavroudis , J.D. Scheff , S.E. Calvano , I.P. Androulakis
Journal of Innate Immunity 5 ( 2) 153 -162
44
2013
PBPK-PD MODELING TO PROVIDE A TRANSLATIONAL RATIONALE BETWEEN DRUGS AND BETWEEN SPECIES: EXAMPLE OF TRAIL FUSION PROTEINS.
M Block , J Jaeger , P Mavroudis , M Hutt
Clinical Pharmacology & Therapeutics 99 S11 -S12
2016
Development of a Minimal Physiologically-Based Pharmacokinetic Modeling/Machine Learning Framework for Early Target Pharmacology Assessment
Panteleimon Mavroudis , Krutika Patidar , Nikhil Pillai , Saroj Dhakal
2024
Incorporating complex drug PK with multiple binding targets into a QSP model to predict combined PD effects
Rebecca Baillie , Jared Cui , Krishnakant Dasika , Hans-Christoph Schneider
534b) Peripheral clock gene entrainment by cortisol
Jeremy D. Scheff , Ioannis Androulakis , Stephen F. Lowry , Panteleimon D. Mavroudis
Systems Biology - Topical Conference at the 2011 AIChE Annual Meeting 61 -64
2011
Mathematical modeling of mammalian circadian clocks affecting drug and disease responses.
William J. Jusko , Panteleimon D. Mavroudis
Journal of Pharmacokinetics and Pharmacodynamics 48 ( 3) 375 -386
2021
On the unphysical hypotheses in pharmacokinetics and oral drug absorption: Time to utilize instantaneous rate coefficients instead of rate constants.
Panteleimon D. Mavroudis , Kosmas Kosmidis , Panos Macheras
European Journal of Pharmaceutical Sciences 130 137 -146
2019
Autonomic dysfunction in SIRS and sepsis
Jeremy D. Scheff , Panteleimon D. Mavroudis , Steve E. Calvano , Stephen F. Lowry
Brain Disorders in Critical Illness 192 -199
3
2013
Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.
Panteleimon D. Mavroudis , John van den Anker , Laurie S. Conklin , Jesse M. Damsker
The Journal of Clinical Pharmacology 59 ( 7) 979 -988
5
2019
The Impact of Stochasticity and Its Control on a Model of the Inflammatory Response
Panteleimon D. Mavroudis , Jeremy D. Scheff , John C. Doyle , Yoram Vodovotz
Computation 7 ( 1) 3
2
2018
A multiscale modeling approach to inflammation: A case study in human endotoxemia
Jeremy D. Scheff , Panteleimon D. Mavroudis , Panagiota T. Foteinou , Gary An
Journal of Computational Physics 244 279 -289
10
2013
ATLAS mPBPK: A MATLAB-Based Tool for Modeling and Simulation of Minimal Physiologically-Based Pharmacokinetic Models
Panteleimon D. Mavroudis , Vivaswath S. Ayyar , William J. Jusko
CPT: Pharmacometrics & Systems Pharmacology 8 ( 8) 557 -566
1
2019
Circadian characteristics of permissive and suppressive effects of cortisol and their role in homeostasis and the acute inflammatory response
Panteleimon D. Mavroudis , Siobhan A. Corbett , Steven E. Calvano , Ioannis P. Androulakis
Bellman Prize in Mathematical Biosciences 260 54 -64
30
2015
Translational applications of evaluating physiologic variability in human endotoxemia
Jeremy D. Scheff , Panteleimon D. Mavroudis , Steve E. Calvano , Ioannis P. Androulakis
Journal of Clinical Monitoring and Computing 27 ( 4) 405 -415
18
2013
Daily variation of gene expression in diverse rat tissues.
Panteleimon D. Mavroudis , Debra C. DuBois , Richard R. Almon , William J. Jusko
PLOS ONE 13 ( 5)
17
2018
Development and validation of a physiology-based model for the prediction of pharmacokinetics/toxicokinetics in rabbits.
Panteleimon D. Mavroudis , Helen E. Hermes , Donato Teutonico , Thomas G. Preuss
PLOS ONE 13 ( 3) 1 -17
7
2018
Dynamical Aspects of Pharmacokinetic/Pharmacodynamic & Quantitative Systems Pharmacology Models
Ioannis Loisios-Konstantinidis , Panteleimon D. Mavroudis , Panos Macheras
Springer, Cham 35 -61
2020
Modeling circadian variability of core-clock and clock-controlled genes in four tissues of the rat
Panteleimon D. Mavroudis , Debra C. DuBois , Richard R. Almon , William J. Jusko
PLOS ONE 13 ( 6) e0197534
9
2018
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.
Laurie S. Conklin , Jesse M. Damsker , Eric P. Hoffman , William J. Jusko
Pharmacological Research 136 140 -150
37
2018
Modeling Physiologic Variability in Human Endotoxemia
Jeremy D. Scheff , Panteleimon D. Mavroudis , Panagiota T. Foteinou , Steve E. Calvano
Critical Reviews in Biomedical Engineering 40 ( 4) 313 -322
18
2012